MX2019012445A - Anticuerpos anti-peptido beta amiloide n3pglu y usos de los mismos. - Google Patents

Anticuerpos anti-peptido beta amiloide n3pglu y usos de los mismos.

Info

Publication number
MX2019012445A
MX2019012445A MX2019012445A MX2019012445A MX2019012445A MX 2019012445 A MX2019012445 A MX 2019012445A MX 2019012445 A MX2019012445 A MX 2019012445A MX 2019012445 A MX2019012445 A MX 2019012445A MX 2019012445 A MX2019012445 A MX 2019012445A
Authority
MX
Mexico
Prior art keywords
n3pglu
amyloid beta
beta peptide
peptide antibodies
antibodies
Prior art date
Application number
MX2019012445A
Other languages
English (en)
Spanish (es)
Inventor
Lu Jirong
Tang Ying
Bradley Demattos Ronald
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MX2019012445A publication Critical patent/MX2019012445A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
    • C12N5/0682—Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0684—Cells of the urinary tract or kidneys
    • C12N5/0686—Kidney cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MX2019012445A 2017-04-20 2018-04-16 Anticuerpos anti-peptido beta amiloide n3pglu y usos de los mismos. MX2019012445A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762487550P 2017-04-20 2017-04-20
PCT/US2018/027718 WO2018194951A1 (en) 2017-04-20 2018-04-16 ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF

Publications (1)

Publication Number Publication Date
MX2019012445A true MX2019012445A (es) 2020-01-13

Family

ID=62111232

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019012445A MX2019012445A (es) 2017-04-20 2018-04-16 Anticuerpos anti-peptido beta amiloide n3pglu y usos de los mismos.
MX2022011817A MX2022011817A (es) 2017-04-20 2019-10-17 Anticuerpos anti-peptido beta amiloide n3pglu y usos de los mismos.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022011817A MX2022011817A (es) 2017-04-20 2019-10-17 Anticuerpos anti-peptido beta amiloide n3pglu y usos de los mismos.

Country Status (28)

Country Link
US (3) US10647759B2 (enExample)
EP (1) EP3612559A1 (enExample)
JP (3) JP6900500B2 (enExample)
KR (2) KR102567295B1 (enExample)
CN (2) CN110582511B (enExample)
AR (1) AR111208A1 (enExample)
AU (2) AU2018255221B2 (enExample)
BR (1) BR112019018810A2 (enExample)
CA (1) CA3058482C (enExample)
CL (1) CL2019002922A1 (enExample)
CO (1) CO2019011349A2 (enExample)
CR (1) CR20190445A (enExample)
DO (1) DOP2019000241A (enExample)
EA (1) EA201992163A1 (enExample)
EC (1) ECSP19075146A (enExample)
IL (1) IL269003B2 (enExample)
JO (1) JOP20190247A1 (enExample)
MA (1) MA50144A (enExample)
MX (2) MX2019012445A (enExample)
NZ (1) NZ758066A (enExample)
PE (1) PE20200011A1 (enExample)
PH (1) PH12019502361A1 (enExample)
SA (1) SA519410311B1 (enExample)
SG (1) SG11201909022PA (enExample)
TW (2) TWI705975B (enExample)
UA (1) UA126806C2 (enExample)
WO (1) WO2018194951A1 (enExample)
ZA (1) ZA202007868B (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201827467A (zh) 2016-11-03 2018-08-01 比利時商健生藥品公司 焦穀胺酸類澱粉蛋白－β之抗體及其用途
JOP20190247A1 (ar) * 2017-04-20 2019-10-20 Lilly Co Eli أجسام بيتا ببتيد النشوانية المضادة لـ N3pGlu واستخداماتها
WO2020193644A1 (en) 2019-03-26 2020-10-01 Janssen Pharmaceutica Nv ANTIBODIES TO PYROGLUTAMATE AMYLOID-ß AND USES THEREOF
WO2021151011A2 (en) * 2020-01-24 2021-07-29 The Board Of Trustees Of Western Michigan University Treatment of neurodegenerative proteinopathies using fas apoptosis inhibitory molecule (faim) or a fragment and/or a mimetic thereof
AU2021355518A1 (en) * 2020-10-02 2023-06-08 Eli Lilly And Company Methods for reducing host cell protein content in protein purification processes
TWI843040B (zh) 2021-01-11 2024-05-21 美商美國禮來大藥廠 抗N3pGlu類澱粉β抗體及其用途
TW202300518A (zh) 2021-03-12 2023-01-01 美商美國禮來大藥廠 抗N3pGlu類澱粉β抗體及其用途
TW202300517A (zh) 2021-03-12 2023-01-01 美商美國禮來大藥廠 抗類澱粉β抗體及其用途
WO2022251048A1 (en) 2021-05-24 2022-12-01 Eli Lilly And Company Anti-amyloid beta antibodies and uses thereof
JP7306745B2 (ja) * 2021-09-16 2023-07-11 株式会社ユニバーサルエンターテインメント 遊技機
JP7306746B2 (ja) * 2021-09-16 2023-07-11 株式会社ユニバーサルエンターテインメント 遊技機
JP7268910B2 (ja) * 2021-09-16 2023-05-08 株式会社ユニバーサルエンターテインメント 遊技機
CA3235104A1 (en) * 2021-10-22 2023-04-27 Kevin BIGLAN O-glcnacase (oga) inhibitor combination therapy
CN118475609A (zh) 2021-10-29 2024-08-09 伊莱利利公司 靶向白细胞介素-34的化合物和方法
TW202336034A (zh) 2021-10-29 2023-09-16 美商美國禮來大藥廠 靶向介白素-34之化合物及方法
KR20240105403A (ko) 2021-10-29 2024-07-05 일라이 릴리 앤드 캄파니 인터류킨-34를 표적화하는 화합물 및 방법
KR20240099347A (ko) 2021-10-29 2024-06-28 일라이 릴리 앤드 캄파니 인터류킨-34를 표적화하는 화합물 및 방법
EP4472679A1 (en) 2022-02-03 2024-12-11 Eli Lilly and Company Regional tau imaging for diagnosing and treating alzheimer's disease
CN117327168A (zh) * 2022-06-24 2024-01-02 厦门大学 B2M-GluN1封闭肽、其药物组合物及用途
AU2023382603A1 (en) * 2022-11-17 2025-07-03 Eli Lilly And Company ANTI-N3pGlu AMYLOID BETA ANTIBODIES, DOSES, AND USES THEREOF
EP4638494A1 (en) 2022-12-22 2025-10-29 BioArctic AB Antibody which binds to abetape3
WO2025106313A1 (en) 2023-11-14 2025-05-22 Eli Lilly And Company Fc RECEPTOR BASED ASSAYS FOR ANALYZING IgG ANTIBODIES
CN118459583B (zh) * 2024-07-11 2024-09-10 齐鲁制药有限公司 抗N3pGlu淀粉样蛋白β抗体及其用途

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100767146B1 (ko) * 2000-02-24 2007-10-15 워싱톤 유니버시티 Ａβ 펩티드를 격리시키는 인간화 항체
US7122374B1 (en) 2002-04-09 2006-10-17 Takaomi Saido Amyloid beta-protein 3(pE)-42 antibodies and uses thereof
CA2487528A1 (en) 2002-07-24 2004-02-12 Innogenetics N.V. Prevention, treatment and diagnosis of diseases associated with beta-amyloid formation and/or aggregation
CA2538220A1 (en) 2003-09-09 2005-03-24 Takeda Pharmaceutical Company Limited Use of antibody
MX2007000998A (es) 2004-07-30 2007-07-11 Rinat Neuroscience Corp Anticuerpos dirigidos peptido beta-amiloide y procedimientos que usan los mismos.
UY29504A1 (es) * 2005-04-29 2006-10-31 Rinat Neuroscience Corp Anticuerpos dirigidos contra el péptido amiloide beta y métodos que utilizan los mismos.
TWI551607B (zh) 2006-07-14 2016-10-01 Ａｃ免疫公司 人類化抗體
WO2009149487A2 (en) 2008-06-12 2009-12-17 Affiris Ag Compounds for treating symptoms associated with parkinson's disease
JP2011527338A (ja) 2008-07-09 2011-10-27 ユニバーシティー オブ チューリッヒ 神経新生を促進する方法
JP5828762B2 (ja) 2008-07-21 2015-12-09 プロビオドルグ エージー 診断用抗体アッセイ
EP2576617B1 (en) 2010-06-04 2016-04-27 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts Universitätsmedizin MONOCLONAL ANTIBODIES TARGETING Aß OLIGOMERS
LT3042917T (lt) * 2010-08-12 2018-05-10 Eli Lilly And Company Antikūnai prieš n3pglu beta amiloidinį peptidą ir jų panaudojimas
WO2012021475A2 (en) 2010-08-12 2012-02-16 Eli Lilly And Company ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF
WO2015175769A1 (en) * 2014-05-15 2015-11-19 Biogen Ma Inc. Methods for the detection of amyloid beta oligomers in biological samples
TWI599358B (zh) 2014-09-16 2017-09-21 美國禮來大藥廠 組合療法
ES3012402T3 (en) * 2015-04-13 2025-04-09 Pfizer Therapeutic antibodies and their uses
JOP20170004B1 (ar) 2016-01-15 2022-09-15 Lilly Co Eli الأجسام المضادة لببتيد بيتا النشوي مضاد N3pGlu واستخداماته
TWI735600B (zh) 2016-07-01 2021-08-11 美商美國禮來大藥廠 抗－N3pGlu類澱粉β肽抗體及其用途
JOP20190247A1 (ar) * 2017-04-20 2019-10-20 Lilly Co Eli أجسام بيتا ببتيد النشوانية المضادة لـ N3pGlu واستخداماتها

Also Published As

Publication number Publication date
ZA202007868B (en) 2023-06-28
JP2021151253A (ja) 2021-09-30
WO2018194951A1 (en) 2018-10-25
AU2018255221A1 (en) 2019-09-19
CN110582511A (zh) 2019-12-17
ECSP19075146A (es) 2019-10-31
CL2019002922A1 (es) 2020-03-13
UA126806C2 (uk) 2023-02-08
AU2021203927B2 (en) 2024-03-21
TWI705975B (zh) 2020-10-01
BR112019018810A2 (pt) 2020-05-05
KR20220011800A (ko) 2022-01-28
KR102352670B1 (ko) 2022-01-19
IL269003A (en) 2019-10-31
AU2018255221B2 (en) 2021-07-01
CN110582511B (zh) 2023-08-08
PE20200011A1 (es) 2020-01-06
EP3612559A1 (en) 2020-02-26
EA201992163A1 (ru) 2020-03-02
US11078261B2 (en) 2021-08-03
CA3058482C (en) 2023-05-09
AU2021203927A1 (en) 2021-07-08
PH12019502361A1 (en) 2020-07-13
CR20190445A (es) 2019-11-06
SG11201909022PA (en) 2019-11-28
JP2020510081A (ja) 2020-04-02
US20180305444A1 (en) 2018-10-25
IL269003B1 (en) 2025-06-01
CN117024583A (zh) 2023-11-10
SA519410311B1 (ar) 2022-03-20
JP2023058623A (ja) 2023-04-25
TW202120541A (zh) 2021-06-01
MA50144A (fr) 2020-07-29
CO2019011349A2 (es) 2019-10-31
JOP20190247A1 (ar) 2019-10-20
JP6900500B2 (ja) 2021-07-07
TWI789644B (zh) 2023-01-11
DOP2019000241A (es) 2019-10-15
TW201902924A (zh) 2019-01-16
CA3058482A1 (en) 2018-10-25
KR102567295B1 (ko) 2023-08-16
IL269003B2 (en) 2025-10-01
MX2022011817A (es) 2022-10-10
US20210371509A1 (en) 2021-12-02
AR111208A1 (es) 2019-06-12
NZ758066A (en) 2022-10-28
US10647759B2 (en) 2020-05-12
KR20190129100A (ko) 2019-11-19
US20200262902A1 (en) 2020-08-20
JP7227312B2 (ja) 2023-02-21
JP7532571B2 (ja) 2024-08-13

Similar Documents

Publication Publication Date Title
MX2019012445A (es) Anticuerpos anti-peptido beta amiloide n3pglu y usos de los mismos.
MX2018008557A (es) Anticuerpos peptidicos beta amiloide anti-n3pglu y usos de los mismos.
CL2020002043A1 (es) Métodos y composiciones para la entrega de proteínas terapeuticas.
CL2019001978A1 (es) Compuestos de 5-metil-1,2,4-oxadiazol-3-ilo.
CY1122987T1 (el) Αντισωματα εναντι αμυλοειδους βητα
CR20170600A (es) Anticuerpos del factor x1 y métodos de uso
HUE053239T2 (hu) Humanizált tau-ellenanyagok Alzheimer-kór kezelésére
BR112018017172A2 (pt) anticorpos monoclonais anti-alfa-sinucleína para prevenção da agregação de tau
MX374012B (es) Formas solidas cristialinas de 6-carboxi-2-(3,5-diclorofenil)-benzoxazol.
BR112019023990A2 (pt) Bis-octa-hidrofenantreno carboxamidas e conjugados de proteína das mesmas
CO2017000346A2 (es) Anticuerpos de unión a protofibrillas aβ
CL2024000459A1 (es) Tubulisinas y conjugados de proteína-tubulisina.
MA46621A (fr) Traitements combinés comprenant l'administration d'imidazopyrazinones
BR112016017620A2 (pt) Composto esteroidal para uso no tratamento da encefalopatia hepática
UY36262A (es) Anticuerpos anti proteína similar a angiopoyetina 4 y métodos de uso
MX2018001592A (es) Composiciones y metodos para el tratamiento y la prevencion de trastornos neurodegenerativos.
IL281083A (en) Adeno-associated viral vectors for the treatment of best disease
LT3413870T (lt) Igmesinas, skirtas panaudoti alzheimerio ligos gydymui
PL3897595T3 (pl) Oftalmiczna kompozycja nutraceutyczna do leczenia schorzeń siatkówki z komponentą neowaskularną
MX2018005097A (es) Anticuerpos altamente potentes que se unen a receptor de muerte 4 y receptor de muerte 5.
ES2680418R1 (es) Uso de un compuesto en la fabricación de un medicamento útil para el tratamiento por activación de la expresión de la proteína CIRP de una enfermedad y composición